The Centers for Disease Control and Prevention on Thursday recommended the Pfizer and Moderna Covid vaccines over Johnson & Johnson’s vaccine.
The CDC’s advisers pointed to the mounting evidence that the company’s vaccine has the potential to set off a rare blood clot disorder that has been linked to 54 cases and 9 deaths in the United States.
The CDC has now made their panel’s advice official and their guidelines have been updated to discourage vaccine providers and adults from receiving J & J’s vaccine.
The panel’s recommendation comes after new data revealed that the risk for blood clotting was higher than previously thought. The highest risk group was women from age 30 to 49.
“I really cannot recommend a vaccine that has been associated with a condition that may lead to death,” said one committee member, Dr. Pablo Sanchez, who is a pediatrician at the Nationwide Children’s Hospital in Ohio.
Despite the CDC and their panel’s decision, J & J’s vaccine will not be taken off the market. It will still be available for those who are “unable or unwilling” to receive Moderna or Pfizer-BioNTech’s vaccines.
Majority of Johnson & Johnson thrombosis cases involved females
Most who reported issues with the J & J vaccine were women between the ages of 18 and 48. One woman died and another female in Nebraska has now been hospitalized with thrombosis and is in critical condition, the officials told reporters.
All the females developed the thrombosis condition between six and 16 days after being vaccinated. Government experts were concerned that an immune system response triggered by the vaccine caused the problems.
At the present time, almost 16 million people in the United States have received Johnson & Johnson shots so far. The vaccine failed to live up to its advertising as a quick, one-shot method for easy vaccination, a strategy that was meant to sway those on the fence with Pfizer and Moderna’s two-dose vaccines.
The Food and Drug Administration updated its guidance on the blood-clotting disorders connected to J & J’s vaccine earlier this week, acknowledging that it increased the chances of clotting while maintaining that the benefits outweighed the risks.
“Today’s updated recommendation emphasizes CDC’s commitment to provide real-time scientific information to the American public,” CDC Director Dr. Rochelle Walensky said in a statement. “I continue to encourage all Americans to get vaccinated and boosted.”
The Johnson & Johnson vaccine first came in for scrutiny on April 9, when the European Medicines Agency said it was investigating reports of four cases of blood clots in people who received the Johnson & Johnson vaccine in the United States.
One case had already occurred in the clinical trials that took place before the vaccine was authorized for emergency use and three occurred in the vaccine clinics after authorization. One of the cases was fatal.